A pharmacist-driven Food and Drug Administration incident surveillance and response program for compounded drugs

• Published in: American journal of health-system pharmacy Vol. 78; no. 15; pp. 1438 - 1443
• Main Authors: Janusziewicz, Ashlee N, Glueck, Shannon N, Park, Sophia Y, Nguyen, Dien N, Rimmel, Susan C, Cascio, Laurelle A, Doh, Gina Y, Martin-Yeboah, Garrette F
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 01.08.2021
• Subjects: Descriptive Report; adverse drug reaction reporting systems; adverse drug event; drug compounding; United States Food and Drug Administration
• ISSN: 1079-2082; 1535-2900
• DOI: 10.1093/ajhp/zxab176

Abstract Purpose To provide an overview of compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, and to describe the pharmacist’s role within the US Food and Drug Administration’s (FDA’s) Compounding Incidents Program, whose efforts are aimed at protecting the public against poor-quality compounded drugs through surveillance, review and response to adverse events and complaints. Summary Compounded drugs may serve an important medical need for patients who cannot be treated with medications approved by FDA; however, compounded drugs are not approved by FDA and are not subject to premarket review for safety, efficacy, or manufacturing quality; thus, they may pose safety risks to patients. Prompt reporting of adverse events or complaints related to compounding is important in identifying these risks and implementing safeguards to protect the public. FDA’s Compounding Incidents Program consists of a team of pharmacists dedicated to the surveillance and review of adverse events and complaints and follow-up actions related to safety risks associated with compounded drugs. Pharmacists are a vital component of FDA’s Compounding Incidents Program, utilizing their clinical skill set and regulatory knowledge to review and act on safety issues that affect public health. Conclusion As FDA continues to expand the Compounding Incidents Program and its efforts to protect the public against poor-quality compounded drugs, we encourage the continued submission of adverse event reports by healthcare professionals and consumers to FDA’s MedWatch reporting system in addition to adverse event reporting compliance by outsourcing facilities.